Former Intellia scientist John Finn reflects on gene editing's evolution and the closure of Tome Biosciences, highlighting the industry's focus on tools over medicines.

Patient in 80s dies after receiving Intellia Therapeutics' CRISPR therapy nex-z for ATTR. Death follows liver injury; exact cause unclear. CEO John Leonard announces trial pause.

In February, a team of scientists achieved a long-held scientific goal — creating a bespoke CRISPR editing therapy to treat a single patient with a unique genetic mutation. “Baby KJ” got his own custo...

With more than 1 million Massachusetts residents expected to lose access to their SNAP benefits next month, these local resources may be able to offer support.

Startup Bexorg, led by Zvonimir Vrselja, keeps human brains alive to test drugs. Their BrainEx system sustains brain cells for 24 hours to improve drug development and reduce animal testing.

Bexorg has collected $23 million in a Series A raise to scale up its human brain experiments, bringing its total funding to $42.5 million, the startup announced Wednesday.

Originally Published: 11 SEP 25 14:36 ET By Alisha Ebrahimji, CNN (CNN) — Multiple Historically Black Universities and Colleges in the South were on lockdown or have cancelled classes on Thursday…

Vasodilatory signals are rapidly communicated across long distances by endothelial-endothelial gap junctions, enabling coordinated dilation of the arterial network during neurovascular coupling.

Amyloid plaques and tau tangles are the most well-known protein structures associated with Alzheimer’s, but a new study bolsters the longstanding notion that there’s a lot more going on in the disease...

FDA Commissioner Marty Makary reportedly attempted to reject KalVista Pharmaceuticals' drug application, sources said. An HHS spokesperson calls the claim 'totally false.'

This review article summarizes the current literature investigating the effects of transient sex hormone fluctuations on large artery endothelial function, primarily concerning the menstrual cycle and the diurnal rhythm of testosterone secretion. Women and men experience acute fluctuations in circulating levels of sex hormones, and there is substantial variability in circulating levels of sex hormones in both sexes. These acute fluctuations in sex hormones generally coincide with alterations in endothelial cell function and in vivo endothelium-dependent vasodilation, and we see that the timing of these acute fluctuations match the timing of cardiovascular events in both women and men. It is important to improve our understanding of how acute fluctuations in sex hormones affect endothelial function in women and men, as clinical cardiovascular complications coincide with these changes. This would allow for the identification of novel therapeutic targets and aid in the prevention and treatment of cardiovascular disease.

Cardiovascular disease (CVD) is the leading cause of death in both men and women, but there are sex differences in the timing and mechanisms of diseas…